𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Early primary biliary cirrhosis: Just delayed or different?

✍ Scribed by K D Lindor

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
147 KB
Volume
26
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

biopsy specimens in 16 of 35 patients. Of note, despite using to be more optimistic about vaccines or immunoadjuvant therapies designed to elicit host anti-HCV specific CTL. vaccinia vectors encoding genotype 1a HCV epitopes in their assays, anti-HCV specific CTL activity was detected in 3 of 9 patients with genotype 1b and 3 of 9 patients with non-DWAIN L. THIELE, M.D. type 1 genotypes as well as in 10 of 17 patients with genotype Liver Unit/Internal Medicine 1a or mixed genotype 1a and 2a infections. Thus despite UT Southwestern Medical Center at Dallas concerns that CTL responses might be underestimated be-Dallas, TX cause of sequence differences between in vivo viral antigens stimulating the response and the recombinant genotype 1a REFERENCES antigens used in in vitro research assays, sufficient CTL re-1. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer sponses appear to be directed against conserved epitopes

πŸ“œ SIMILAR VOLUMES

Long-term ursodeoxycholic acid delays hi
Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
✍ Paul Angulo; Kenneth P. Batts; Terry M. Therneau; Roberta A. Jorgensen; E. Rolla πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 50 KB πŸ‘ 1 views

Primary biliary cirrhosis (PBC) is a progressive cholestatic liver disease frequently leading to development of cirrhosis and its complications. Ursodeoxycholic acid (UDCA) is a beneficial medical therapy for patients with PBC. Improvement in some histological features, but not in histological stage

Differences between Caucasian, African A
Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States
✍ Marion G. Peters; Adrian M. Di Bisceglie; Kris V. Kowdley; Nancy L. Flye; Velimi πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 114 KB

Primary biliary cirrhosis (PBC) is an uncommon chronic cholestatic liver disease that primarily afflicts young and middle-aged Caucasian women; there are limited data on the clinical presentation and disease severity among non-Caucasian patients with this disease. The goal of this study was to exami

Anti-gp210 and anti-centromere antibodie
Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis
✍ Minoru Nakamura; Hisayoshi Kondo; Tsuyoshi Mori; Atsumasa Komori; Mutsumi Matsuy πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 229 KB πŸ‘ 1 views

The predictive role of antinuclear antibodies (ANAs) remains elusive in the long-term outcome of primary biliary cirrhosis (PBC). The progression of PBC was evaluated in association with ANAs using stepwise Cox proportional hazard regression and an unconditional stepwise logistic regression model ba

Differences in the metabolism and dispos
Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis
✍ Pietro Invernizzi; Kenneth D. Setchell; Andrea Crosignani; Pier Maria Battezzati πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 180 KB πŸ‘ 1 views

The clinical effectiveness of ursodeoxycholate in the treatment of liver disease may be limited by its poor absorption and extensive biotransformation. Because in vitro and in vivo studies suggest that the more hydrophilic bile acid tauroursodeoxycholate has greater beneficial effects than ursodeoxy